Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 7/20 | 0.72 |
| ▸ | MEN1 | O00255 | 8/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12692440 | 0.89 | CHRM4 (0.71) | CHRM4MEN1KMT2AATMSMN1; SMN2 | |
| SCHEMBL6706014 | 0.87 | CHRM4 (0.54) | CHRM4 | |
| SCHEMBL6223589 | 0.87 | MEN1 (0.55) | CHRM4MEN1KMT2AATMSMN1; SMN2 | |
| SCHEMBL29432089 | 0.83 | CHRM4 (1.00) | CHRM4MEN1KMT2A | |
| SCHEMBL6705916 | 0.82 | CHRM4 (0.69) | CHRM4MEN1KMT2A | |
| SCHEMBL6705926 | 0.79 | CHRM4 (0.73) | CHRM4 | |
| SCHEMBL6705886 | 0.79 | CHRM4 (0.55) | CHRM4 | |
| SCHEMBL6705872 | 0.79 | CHRM4 (0.67) | CHRM4MEN1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL6704792 | 0.77 | MEN1 (0.61) | CHRM4MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL3868658 | 0.77 | CHRM4 (0.66) | CHRM4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | CHRM4 467/4885MEN1 995/4885KMT2A 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.